Page 4 of 10

Causes & Drivers

Resistance is natural — but the speed at which it is now emerging is man-made. Five interlocking drivers push it forward, spanning human medicine, farming, the environment and economics.

1. Overuse and misuse in human medicine

Every course of antibiotics applies selection pressure, so unnecessary courses breed resistance while delivering no benefit. Studies in high-income countries consistently find that a large share of antibiotic prescriptions — commonly estimated at around 30% in US outpatient care, and up to half by some measures — are unnecessary or suboptimal, often given for viral illnesses such as colds, flu and most sore throats, against which antibiotics do nothing.

2. Massive use in food animals

By most estimates, animals — not people — consume the majority of the world's antimicrobials: roughly 70–73% of all antibiotics sold globally are used in food-producing animals, often given to whole healthy herds and flocks to prevent disease in crowded conditions or, historically, simply to make animals grow faster.

3. Poor infection prevention, sanitation and vaccination gaps

Every infection prevented is an antibiotic course avoided. The reverse is also true: where clean water, sanitation, hygiene and vaccines are lacking, infections multiply — and so does antibiotic use and resistance.

4. Environmental contamination

The environment is the often-forgotten third leg of the problem. Antibiotic residues, resistant bacteria and resistance genes enter soil and water through human sewage, farm run-off and — at hotspots — waste from pharmaceutical manufacturing, where antibiotic concentrations in effluent can exceed levels found in the blood of treated patients. Rivers and wastewater act as mixing vessels where environmental bacteria, human pathogens and resistance genes meet and trade DNA.

5. A broken market for new antibiotics

While resistance rises, the supply of new drugs has stalled. Antibiotics are cheap, taken briefly, and — if new and precious — deliberately held in reserve, so they earn little. Most major pharmaceutical companies abandoned antibacterial research decades ago, and several small biotechs have gone bankrupt after successfully getting a new antibiotic approved. Fixing these incentives is a central theme of the global response and innovation pages.

Accelerants: travel, conflict and pandemics

International travel and trade move resistant organisms between continents in hours. Conflict zones combine wounds, collapsed health systems and unregulated antibiotic use — highly resistant strains have spread from recent war zones. The COVID-19 pandemic made things worse too: large numbers of hospitalised patients received antibiotics they did not need, and US data showed resistant hospital infections and deaths jumping about 15% in 2020.

Why this is a “One Health” problem

Human medicine, animal farming and the environment form one connected reservoir of microbes and genes. Action in only one sector gets undone by the other two — which is why WHO, the UN's food and agriculture bodies (FAO), the World Organisation for Animal Health (WOAH) and the UN Environment Programme now tackle AMR jointly under the banner of One Health.

Sources for this page

  • “Antibiotic Use in Livestock and Environmental Antibiotic Resistance: A Narrative Review”, Environmental Health Insights, 2025 — bioone.org/journals/environmental-health-insights
  • “Livestock Antibiotics Use and Antimicrobial Resistance”, PMC, 2025 — pmc.ncbi.nlm.nih.gov/articles/PMC12189104/
  • Alliance to Save Our Antibiotics, “Antibiotic Overuse in Livestock Farming” — saveourantibiotics.org
  • CDC, “COVID-19: U.S. Impact on Antimicrobial Resistance”, Special Report 2022 — cdc.gov
  • WHO fact sheet, “Antimicrobial resistance” — who.int/news-room/fact-sheets/detail/antimicrobial-resistance